{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:36:27Z","timestamp":1763746587240,"version":"3.45.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"DOI":"10.7759\/cureus.97446","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:24:09Z","timestamp":1763745849000},"source":"Crossref","is-referenced-by-count":0,"title":["In Search of Commonality: Physiological and Therapeutic Potentials of Sodium-Glucose Transport Protein 2 Inhibitors in Cardiovascular and Chronic Kidney Diseases"],"prefix":"10.7759","author":[{"given":"Khalid","family":"Sawalha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Alamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landon","family":"Bruich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Lopez Candales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth GA","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al.. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020, 76:2982-3021. 10.1016\/j.jacc.2020.11.010","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","unstructured":"Global, regional, and national burden of chronic kidney disease, 1990-2017. a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020, 395:709-33. 10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Hill NR","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FD. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS One. 2016, 11:e0158765. 10.1371\/journal.pone.0158765","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8871-2_1","article-title":"Prevalence and disease burden of chronic kidney disease","volume":"1165","author":"Lv JC","year":"2019","unstructured":"Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019, 1165:3-15. 10.1007\/978-981-13-8871-2_1","journal-title":"Adv Exp Med Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5888\/pcd13.160211","article-title":"Heart disease and cancer deaths: trends and projections in the United States, 1969-2020","volume":"13","author":"Weir HK","year":"2016","unstructured":"Weir HK, Anderson RN, Coleman King SM, et al.. Heart disease and cancer deaths: trends and projections in the United States, 1969-2020. Prev Chronic Dis. 2016, 13:E157. 10.5888\/pcd13.160211","journal-title":"Prev Chronic Dis"},{"key":"ref6","article-title":"CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013","volume":"63","author":"Johnson NB","year":"2014","unstructured":"Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013. MMWR Suppl. 2014, 63:3-27.","journal-title":"MMWR Suppl"},{"key":"ref7","article-title":"Mortality in the United States","author":"Xu J","year":"2015","unstructured":"Xu J, Murphy SL, Kochanek KD, et al.. Mortality in the United States. CDC, 2015-2016."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese G","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017, 3:7-11. 10.15420\/cfr.2016:25:2","journal-title":"Card Fail Rev"},{"key":"ref9","article-title":"Recent trends in heart failure-related mortality: United States, 2000-2014","author":"Ni H","year":"2015","unstructured":"Ni H, Xu J. Recent trends in heart failure-related mortality: United States, 2000-2014. NCHS Data Brief. 2015, 1-8.","journal-title":"NCHS Data Brief"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger VL","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021, 128:1421-34. 10.1161\/CIRCRESAHA.121.318172","journal-title":"Circ Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.107.743146","article-title":"Death in heart failure: a community perspective","volume":"1","author":"Henkel DM","year":"2008","unstructured":"Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008, 1:91-7. 10.1161\/CIRCHEARTFAILURE.107.743146","journal-title":"Circ Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.004. Epub 2013 Mar 6","article-title":"Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"9","author":"Rooke TW","year":"2013","unstructured":"Rooke TW, Hirsch AT, Misra S, et al.. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, 9:1555-70. 10.1016\/j.jacc.2013.01.004. Epub 2013 Mar 6","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg PG","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PW, et al.. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007, 297:1197-206. 10.1001\/jama.297.11.1197","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/nu11040722","article-title":"Lipid accumulation and chronic kidney disease","volume":"11","author":"Gai Z","year":"2019","unstructured":"Gai Z, Wang T, Visentin M, Kullak-Ublick GA, Fu X, Wang Z. Lipid accumulation and chronic kidney disease. Nutrients. 2019, 11:10.3390\/nu11040722","journal-title":"Nutrients"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1095211","article-title":"Obesity-related kidney disease: beyond hypertension and insulin-resistance","volume":"13","author":"Arabi T","year":"2022","unstructured":"Arabi T, Shafqat A, Sabbah BN, et al.. Obesity-related kidney disease: beyond hypertension and insulin-resistance. Front Endocrinol (Lausanne). 2022, 13:1095211. 10.3389\/fendo.2022.1095211","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02262-7","article-title":"Correction to: Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance - preliminary results from the CARYATID study","volume":"23","author":"Santulli G","year":"2024","unstructured":"Santulli G, Visco V, Ciccarelli M, et al.. Correction to: Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance - preliminary results from the CARYATID study. Cardiovasc Diabetol. 2024, 23:180. 10.1186\/s12933-024-02262-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.08.046","article-title":"CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies","volume":"278","author":"Reiss AB","year":"2018","unstructured":"Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D'Avino R Jr, De Leon J. CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies. Atherosclerosis. 2018, 278:49-59. 10.1016\/j.atherosclerosis.2018.08.046","journal-title":"Atherosclerosis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1125829","article-title":"Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning","volume":"14","author":"Cao Y","year":"2023","unstructured":"Cao Y, Du Y, Jia W, et al.. Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning. Front Endocrinol (Lausanne). 2023, 14:1125829. 10.3389\/fendo.2023.1125829","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar JA","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al.. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024, 83:109-279. 10.1016\/j.jacc.2023.08.017","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe BP","year":"2013","unstructured":"Krijthe BP, Kunst A, Benjamin EJ, et al.. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013, 34:2746-51. 10.1093\/eurheartj\/eht280","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2008.01403.x","article-title":"Frequency analysis of atrial electrograms identifies conduction pathways from the left to the right atrium during atrial fibrillation-studies in two canine models","volume":"20","author":"Ryu K","year":"2009","unstructured":"Ryu K, Sahadevan J, Khrestian CM, Stambler BS, Waldo AL. Frequency analysis of atrial electrograms identifies conduction pathways from the left to the right atrium during atrial fibrillation-studies in two canine models. J Cardiovasc Electrophysiol. 2009, 20:667-74. 10.1111\/j.1540-8167.2008.01403.x","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-021-00510-5","article-title":"Left atrial myopathy in atrial fibrillation and heart failure: Clinical implications, mechanisms, and therapeutic targets","volume":"18","author":"Peigh G","year":"2021","unstructured":"Peigh G, Shah SJ, Patel RB. Left atrial myopathy in atrial fibrillation and heart failure: Clinical implications, mechanisms, and therapeutic targets. Curr Heart Fail Rep. 2021, 18:85-98. 10.1007\/s11897-021-00510-5","journal-title":"Curr Heart Fail Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1747493020909545","article-title":"Global stroke statistics 2019","volume":"15","author":"Kim J","year":"2020","unstructured":"Kim J, Thayabaranathan T, Donnan GA, et al.. Global stroke statistics 2019. Int J Stroke. 2020, 15:819-38. 10.1177\/1747493020909545","journal-title":"Int J Stroke"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12245","article-title":"Global stroke statistics","volume":"9","author":"Thrift AG","year":"2014","unstructured":"Thrift AG, Cadilhac DA, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Donnan GA. Global stroke statistics. Int J Stroke. 2014, 9:6-18. 10.1111\/ijs.12245","journal-title":"Int J Stroke"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/1747493016676285","article-title":"Global stroke statistics","volume":"12","author":"Thrift AG","year":"2017","unstructured":"Thrift AG, Thayabaranathan T, Howard G, et al.. Global stroke statistics. Int J Stroke. 2017, 12:13-32. 10.1177\/1747493016676285","journal-title":"Int J Stroke"},{"key":"ref26","unstructured":"World Stroke Organization. Global stroke fact sheet 2022. (2022). Accessed. May 13, 2025: https:\/\/www.world-stroke.org\/assets\/downloads\/WSO_Global_Stroke_Fact_Sheet.pdf."},{"key":"ref27","unstructured":"Centers for Disease Control and Prevention. Stroke Facts. (2024). Accessed. May 13, 2025: https:\/\/www.cdc.gov\/stroke\/facts.htm."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi A","year":"2024","unstructured":"Mocumbi A, Humbert M, Saxena A, et al.. Pulmonary hypertension. Nat Rev Dis Primers. 2024, 10:1. 10.1038\/s41572-023-00486-7","journal-title":"Nat Rev Dis Primers"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-1468","article-title":"Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities","volume":"15","author":"Singh H","year":"2023","unstructured":"Singh H, Agarwal L, Jani C, et al.. Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities. J Thorac Dis. 2023, 15:3256-72. 10.21037\/jtd-22-1468","journal-title":"J Thorac Dis"},{"key":"ref30","article-title":"illustrative of renal disease, accompanied with the secretion of albuminous urine","volume":"1836","author":"Bright R. Cases and observations","unstructured":"Bright R. Cases and observations. illustrative of renal disease, accompanied with the secretion of albuminous urine. Guy\u2019s Hosp Trans. 1836:338-379.","journal-title":"Guy\u2019s Hosp Trans"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002273","article-title":"Chronic kidney disease management in the United Kingdom: NEOERICA project results","volume":"72","author":"Stevens PE","year":"2007","unstructured":"Stevens PE, O'Donoghue DJ, de Lusignan S, et al.. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007, 72:92-9. 10.1038\/sj.ki.5002273","journal-title":"Kidney Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function","volume":"26","author":"Thompson S","year":"2015","unstructured":"Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015, 26:2504-11. 10.1681\/ASN.2014070714","journal-title":"J Am Soc Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster AC","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, et al.. Chronic kidney disease. Lancet. 2017, 389:1238-52. 10.1016\/S0140-6736(16)32064-5","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski J","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. Circulation. 2021, 143:1157-72. 10.1161\/CIRCULATIONAHA.120.050686","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111111","article-title":"Prevalence, predictors, and outcomes of pulmonary hypertension in CKD","volume":"27","author":"Navaneethan SD","year":"2016","unstructured":"Navaneethan SD, Roy J, Tao K, et al.. Prevalence, predictors, and outcomes of pulmonary hypertension in CKD. J Am Soc Nephrol. 2016, 27:877-86. 10.1681\/ASN.2014111111","journal-title":"J Am Soc Nephrol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00355-0","article-title":"Prevalence and mortality of pulmonary hypertension in ESRD: a systematic review and meta-analysis","volume":"198","author":"Schoenberg NC","year":"2020","unstructured":"Schoenberg NC, Argula RG, Klings ES, Wilson KC, Farber HW. Prevalence and mortality of pulmonary hypertension in ESRD: a systematic review and meta-analysis. Lung. 2020, 198:535-45. 10.1007\/s00408-020-00355-0","journal-title":"Lung"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/039139880102401004","article-title":"Uremic toxicity: present state of the art","volume":"24","author":"Vanholder R","year":"2001","unstructured":"Vanholder R, Argil\u00e9s A, Baurmeister U, et al.. Uremic toxicity: present state of the art. Int J Artif Organs. 2001, 24:695-725. 10.1177\/039139880102401004","journal-title":"Int J Artif Organs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.686249","article-title":"Uremic toxins: an alarming danger concerning the cardiovascular system","volume":"12","author":"Falconi CA","year":"2021","unstructured":"Falconi CA, Junho CV, Foga\u00e7a-Ruiz F, Vernier IC, da Cunha RS, Stinghen AE, Carneiro-Ramos MS. Uremic toxins: an alarming danger concerning the cardiovascular system. Front Physiol. 2021, 12:686249. 10.3389\/fphys.2021.686249","journal-title":"Front Physiol"},{"key":"ref39","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39:1-266.","journal-title":"Am J Kidney Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey AS","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, et al.. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67:2089-100. 10.1111\/j.1523-1755.2005.00365.x","journal-title":"Kidney Int"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey AS","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, et al.. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139:137-47. 10.7326\/0003-4819-139-2-200307150-00013","journal-title":"Ann Intern Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.76","article-title":"Abstract","volume":"3","year":"2012","unstructured":"Abstract. Kidney Int Suppl (2011). 2012, 3.4. 10.1038\/kisup.2012.76","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14186","article-title":"Chronic kidney disease: definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk","volume":"23","author":"Wilson S","year":"2021","unstructured":"Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G. Chronic kidney disease: definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. J Clin Hypertens (Greenwich). 2021, 23:831-4. 10.1111\/jch.14186","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita K","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, et al.. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010, 375:2073-81. 10.1016\/S0140-6736(10)60674-5","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.538132","article-title":"Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study","volume":"112","author":"Arnl\u00f6v J","year":"2005","unstructured":"Arnl\u00f6v J, Evans JC, Meigs JB, et al.. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005, 112:969-75. 10.1161\/CIRCULATIONAHA.105.538132","journal-title":"Circulation"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S373160","article-title":"Association between serum albumin level and microvascular complications of type 2 diabetes mellitus","volume":"15","author":"Zhang J","year":"2022","unstructured":"Zhang J, Deng Y, Wan Y, He S, Cai W, Xu J. Association between serum albumin level and microvascular complications of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2022, 15:2173-82. 10.2147\/DMSO.S373160","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020301","article-title":"Association of mildly reduced kidney function with cardiovascular disease: The Framingham Heart Study","volume":"10","author":"Ataklte F","year":"2021","unstructured":"Ataklte F, Song RJ, Upadhyay A, Musa Yola I, Vasan RS, Xanthakis V. Association of mildly reduced kidney function with cardiovascular disease: The Framingham Heart Study. J Am Heart Assoc. 2021, 10:e020301. 10.1161\/JAHA.120.020301","journal-title":"J Am Heart Assoc"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73","article-title":"Notice","volume":"3","year":"2012","unstructured":"Notice. Kidney Int. 2012, 3.1. 10.1038\/kisup.2012.73","journal-title":"Kidney Int"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.07.037","article-title":"Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database","volume":"96","author":"Folkerts K","year":"2021","unstructured":"Folkerts K, Petruski-Ivleva N, Comerford E, et al.. Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database. Mayo Clin Proc. 2021, 96:975-86. 10.1016\/j.mayocp.2020.07.037","journal-title":"Mayo Clin Proc"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual\u2010participant data meta\u2010analysis in a global consortium","volume":"78","author":"Shin JI","year":"2021","unstructured":"Shin JI, Chang AR, Grams ME, et al.. Albuminuria testing in hypertension and diabetes: an individual\u2010participant data meta\u2010analysis in a global consortium. Hypertension. 2021, 78:1042-52. 10.1161\/HYPERTENSIONAHA.121.17323","journal-title":"Hypertension"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz N","year":"2021","unstructured":"Stempniewicz N, Vassalotti JA, Cuddeback JK, et al.. Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations. Diabetes Care. 2021, 44:2000-9. 10.2337\/dc20-2715","journal-title":"Diabetes Care"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay JI","year":"2024","unstructured":"Barzilay JI, Farag YM, Durthaler J. Albuminuria: an underappreciated risk factor for cardiovascular disease. J Am Heart Assoc. 2024, 13:e030131. 10.1161\/JAHA.123.030131","journal-title":"J Am Heart Assoc"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and functional changes with the aging kidney","volume":"23","author":"Denic A","year":"2016","unstructured":"Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016, 23:19-28. 10.1053\/j.ackd.2015.08.004","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2217\/cpr.14.46","article-title":"Chronic kidney disease in the elderly: evaluation and management","volume":"11","author":"Mallappallil M","year":"2014","unstructured":"Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014, 11:525-35. 10.2217\/cpr.14.46","journal-title":"Clin Pract (Lond)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli M","year":"2006","unstructured":"Tonelli M, Wiebe N, Culleton B, et al.. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006, 17:2034-47. 10.1681\/ASN.2005101085","journal-title":"J Am Soc Nephrol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al.. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019, 74:1376-414. 10.1016\/j.jacc.2019.03.009","journal-title":"J Am Coll Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V781106","article-title":"Aging and the kidney","volume":"7","author":"Epstein M","year":"1996","unstructured":"Epstein M. Aging and the kidney. J Am Soc Nephrol. 1996, 7:1106-22. 10.1681\/ASN.V781106","journal-title":"J Am Soc Nephrol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.155.3.2117353","article-title":"The thickness of the renal parenchyma decreases with age: a CT study of 360 patients","volume":"155","author":"Gourtsoyiannis N","year":"1990","unstructured":"Gourtsoyiannis N, Prassopoulos P, Cavouras D, Pantelidis N. The thickness of the renal parenchyma decreases with age: a CT study of 360 patients. AJR Am J Roentgenol. 1990, 155:541-4. 10.2214\/ajr.155.3.2117353","journal-title":"AJR Am J Roentgenol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.34.3.309","article-title":"Senescence and the renal vasculature in normal man","volume":"34","author":"Hollenberg NK","year":"1974","unstructured":"Hollenberg NK, Adams DF, Solomon HS, Rashid A, Abrams HL, Merrill JP. Senescence and the renal vasculature in normal man. Circ Res. 1974, 34:309-16. 10.1161\/01.res.34.3.309","journal-title":"Circ Res"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017040421","article-title":"Structural and functional changes in human kidneys with healthy aging","volume":"28","author":"Hommos MS","year":"2017","unstructured":"Hommos MS, Glassock RJ, Rule AD. Structural and functional changes in human kidneys with healthy aging. J Am Soc Nephrol. 2017, 28:2838-44. 10.1681\/ASN.2017040421","journal-title":"J Am Soc Nephrol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315435","article-title":"Structural and Functional Changes in Aging Kidneys","volume":"23","author":"Dybiec J","year":"2022","unstructured":"Dybiec J, Szlagor M, M\u0142ynarska E, et al.. Structural and Functional Changes in Aging Kidneys. Int J Mol Sci. 2022, 23:10.3390\/ijms232315435","journal-title":"Int J Mol Sci"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015121308","article-title":"Renal aging: causes and consequences","volume":"28","author":"O'Sullivan ED","year":"2017","unstructured":"O'Sullivan ED, Hughes J, Ferenbach DA. Renal aging: causes and consequences. J Am Soc Nephrol. 2017, 28:407-20. 10.1681\/ASN.2015121308","journal-title":"J Am Soc Nephrol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.0703","article-title":"Aging and renal disease: old questions for new challenges","volume":"12","author":"Chou YH","year":"2021","unstructured":"Chou YH, Chen YM. Aging and renal disease: old questions for new challenges. Aging Dis. 2021, 12:515-28. 10.14336\/AD.2020.0703","journal-title":"Aging Dis"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V112319","article-title":"Effect of gender on the progression of nondiabetic renal disease: a meta-analysis","volume":"11","author":"Neugarten J","year":"2000","unstructured":"Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000, 11:319-29. 10.1681\/ASN.V112319","journal-title":"J Am Soc Nephrol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.968792","article-title":"Sex\/gender differences in cardiovascular disease prevention: what a difference a decade makes","volume":"124","author":"Mosca L","year":"2011","unstructured":"Mosca L, Barrett-Connor E, Wenger NK. Sex\/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011, 124:2145-54. 10.1161\/CIRCULATIONAHA.110.968792","journal-title":"Circulation"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2011.01.007","article-title":"Subclinical atherosclerotic changes related to chronic kidney disease in asymptomatic black and white young adults: the Bogalusa heart study","volume":"21","author":"Dasmahapatra P","year":"2011","unstructured":"Dasmahapatra P, Srinivasan SR, Mokha J, Fernandez C, Chen W, Xu J, Berenson GS. Subclinical atherosclerotic changes related to chronic kidney disease in asymptomatic black and white young adults: the Bogalusa heart study. Ann Epidemiol. 2011, 21:311-7. 10.1016\/j.annepidem.2011.01.007","journal-title":"Ann Epidemiol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.181","article-title":"Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease","volume":"14","author":"Carrero JJ","year":"2018","unstructured":"Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018, 14:151-64. 10.1038\/nrneph.2017.181","journal-title":"Nat Rev Nephrol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-022-02074-3","article-title":"Chronic kidney disease is more prevalent among women but more men than women are under nephrological care: analysis from six outpatient clinics in Austria 2019","volume":"135","author":"Lewandowski MJ","year":"2023","unstructured":"Lewandowski MJ, Krenn S, Kurnikowski A, et al.. Chronic kidney disease is more prevalent among women but more men than women are under nephrological care: analysis from six outpatient clinics in Austria 2019. Wien Klin Wochenschr. 2023, 135:89-96. 10.1007\/s00508-022-02074-3","journal-title":"Wien Klin Wochenschr"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.014","article-title":"US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States","volume":"67","author":"Saran R","year":"2016","unstructured":"Saran R, Li Y, Robinson B, et al.. US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016, 67:Svii, S1-305. 10.1053\/j.ajkd.2015.12.014","journal-title":"Am J Kidney Dis"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1097\/01.asn.0000091586.46532.b4","article-title":"Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States","volume":"14","author":"Hsu CY","year":"2003","unstructured":"Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003, 14:2902-7. 10.1097\/01.asn.0000091586.46532.b4","journal-title":"J Am Soc Nephrol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.047480","article-title":"Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008","volume":"125","author":"Rosamond WD","year":"2012","unstructured":"Rosamond WD, Chambless LE, Heiss G, et al.. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. Circulation. 2012, 125:1848-57. 10.1161\/CIRCULATIONAHA.111.047480","journal-title":"Circulation"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: A report from the American Heart Association","volume":"135","author":"Benjamin EJ","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, et al.. Heart disease and stroke statistics\u20142017 update: A report from the American Heart Association. Circulation. 2017, 135:e146-603. 10.1161\/CIR.0000000000000485","journal-title":"Circulation"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2023.03.011","article-title":"Updates in cardiorenal syndrome","volume":"107","author":"McCallum W","year":"2023","unstructured":"McCallum W, Testani JM. Updates in cardiorenal syndrome. Med Clin North Am. 2023, 107:763-80. 10.1016\/j.mcna.2023.03.011","journal-title":"Med Clin North Am"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami J","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JE, et al.. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019, 139:e840-78. 10.1161\/CIR.0000000000000664","journal-title":"Circulation"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer T","year":"2022","unstructured":"Speer T, Dimmeler S, Schunk SJ, Fliser D, Ridker PM. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat Rev Nephrol. 2022, 18:762-78. 10.1038\/s41581-022-00621-9","journal-title":"Nat Rev Nephrol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020182","article-title":"Review on inflammation markers in chronic kidney disease","volume":"9","author":"Petreski T","year":"2021","unstructured":"Petreski T, Piko N, Ekart R, Hojs R, Bevc S. Review on inflammation markers in chronic kidney disease. Biomedicines. 2021, 9:10.3390\/biomedicines9020182","journal-title":"Biomedicines"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.03.012","article-title":"MicroRNA-10 negatively regulates inflammation in diabetic kidney via targeting activation of the NLRP3 inflammasome","volume":"29","author":"Ding H","year":"2021","unstructured":"Ding H, Li J, Li Y, et al.. MicroRNA-10 negatively regulates inflammation in diabetic kidney via targeting activation of the NLRP3 inflammasome. Mol Ther. 2021, 29:2308-20. 10.1016\/j.ymthe.2021.03.012","journal-title":"Mol Ther"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232714","article-title":"Innate immunity and CKD: is there a significant association?","volume":"12","author":"Plonsky-Toder M","year":"2023","unstructured":"Plonsky-Toder M, Magen D, Pollack S. Innate immunity and CKD: is there a significant association?. Cells. 2023, 12:10.3390\/cells12232714","journal-title":"Cells"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson KV","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019, 19:477-89. 10.1038\/s41577-019-0165-0","journal-title":"Nat Rev Immunol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz P","year":"2016","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016, 16:407-20. 10.1038\/nri.2016.58","journal-title":"Nat Rev Immunol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate A","year":"2020","unstructured":"Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020, 126:1260-80. 10.1161\/CIRCRESAHA.120.315937","journal-title":"Circ Res"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu J","year":"2023","unstructured":"Xu J, N\u00fa\u00f1ez G. The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci. 2023, 48:331-44. 10.1016\/j.tibs.2022.10.002","journal-title":"Trends Biochem Sci"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000001448","article-title":"Inflammasomes as potential mediators of adverse cardiovascular events in diabetes and lupus: more questions than answers","volume":"24","author":"L\u00f3pez-Candales A","year":"2023","unstructured":"L\u00f3pez-Candales A, Sawalha K, Vila LM. Inflammasomes as potential mediators of adverse cardiovascular events in diabetes and lupus: more questions than answers. J Cardiovasc Med (Hagerstown). 2023, 24:279-82. 10.2459\/JCM.0000000000001448","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo S","year":"2018","unstructured":"Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018, 15:203-14. 10.1038\/nrcardio.2017.161","journal-title":"Nat Rev Cardiol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cophys.2020.09.013","article-title":"The inflammasome in heart failure","volume":"19","author":"Mezzaroma E","year":"2021","unstructured":"Mezzaroma E, Abbate A, Toldo S. The inflammasome in heart failure. Curr Opin Physiol. 2021, 19:105-12. 10.1016\/j.cophys.2020.09.013","journal-title":"Curr Opin Physiol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111488","article-title":"The initial human atherosclerotic lesion and lipoprotein modification-a deep connection","volume":"22","author":"Torzewski M","year":"2021","unstructured":"Torzewski M. The initial human atherosclerotic lesion and lipoprotein modification-a deep connection. Int J Mol Sci. 2021, 22:10.3390\/ijms222111488","journal-title":"Int J Mol Sci"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-022-01725-x","article-title":"NLRP3 inflammasome in atherosclerosis: putting out the fire of inflammation","volume":"46","author":"Shao BZ","year":"2023","unstructured":"Shao BZ, Xu HY, Zhao YC, Zheng XR, Wang F, Zhao GR. NLRP3 inflammasome in atherosclerosis: putting out the fire of inflammation. Inflammation. 2023, 46:35-46. 10.1007\/s10753-022-01725-x","journal-title":"Inflammation"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.13","article-title":"NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases","volume":"10","author":"Wang Y","year":"2020","unstructured":"Wang Y, Liu X, Shi H, Yu Y, Yu Y, Li M, Chen R. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. Clin Transl Med. 2020, 10:91-106. 10.1002\/ctm2.13","journal-title":"Clin Transl Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.141713","article-title":"Thrombospondins, their polymorphisms, and cardiovascular disease","volume":"27","author":"Stenina OI","year":"2007","unstructured":"Stenina OI, Topol EJ, Plow EF. Thrombospondins, their polymorphisms, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007, 27:1886-94. 10.1161\/ATVBAHA.107.141713","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00251.2021","article-title":"In the balance: how do thrombospondins contribute to the cellular pathophysiology of cardiovascular disease?","volume":"321","author":"Forbes T","year":"2021","unstructured":"Forbes T, Pauza AG, Adams JC. In the balance: how do thrombospondins contribute to the cellular pathophysiology of cardiovascular disease?. Am J Physiol Cell Physiol. 2021, 321:C826-45. 10.1152\/ajpcell.00251.2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.6515\/acs20140630d","article-title":"Association of plasma thrombospondin-1 level with cardiovascular disease and mortality in hemodialysis patients","volume":"31","author":"Huang CL","year":"2015","unstructured":"Huang CL, Jong YS, Wu YW, et al.. Association of plasma thrombospondin-1 level with cardiovascular disease and mortality in hemodialysis patients. Acta Cardiol Sin. 2015, 31:113-9. 10.6515\/acs20140630d","journal-title":"Acta Cardiol Sin"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)34336-3","article-title":"Isolation and characterization of a high molecular weight glycoprotein from human blood platelets","volume":"10","author":"Lawler JW","year":"1978","unstructured":"Lawler JW, Slayter HS, Coligan JE. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem. 1978, 10:8609-16. 10.1016\/S0021-9258(17)34336-3","journal-title":"J Biol Chem"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/296069","article-title":"Thrombospondin-1: multiple paths to inflammation","volume":"2011","author":"Lopez-Dee Z","year":"2011","unstructured":"Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011, 2011:296069. 10.1155\/2011\/296069","journal-title":"Mediators Inflamm"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006627","article-title":"Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2","volume":"2","author":"Lawler PR","year":"2012","unstructured":"Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med. 2012, 2:a006627. 10.1101\/cshperspect.a006627","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2024.01.010","article-title":"Thrombospondin-1 drives cardiac remodeling in chronic kidney disease","volume":"9","author":"Julovi SM","year":"2024","unstructured":"Julovi SM, Trinh K, Robertson H, et al.. Thrombospondin-1 drives cardiac remodeling in chronic kidney disease. JACC Basic Transl Sci. 2024, 9:607-27. 10.1016\/j.jacbts.2024.01.010","journal-title":"JACC Basic Transl Sci"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019","volume":"42","year":"2019","unstructured":"Pharmacologic approaches to glycemic treatment. Standards of medical care in diabetes-2019. Diabetes Care. 2019, 42:S90-102. 10.2337\/dc19-S009","journal-title":"Diabetes Care"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni L","year":"2020","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020, 19:98. 10.1186\/s12933-020-01071-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle KR","year":"2021","unstructured":"Tuttle KR, Brosius FC 3rd, Cavender MA, et al.. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Diabetes. 2021, 70:1-16. 10.2337\/dbi20-0040","journal-title":"Diabetes"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer A","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia. 2017, 60:568-73. 10.1007\/s00125-016-4134-x","journal-title":"Diabetologia"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-014-2262-5","article-title":"Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats","volume":"400","author":"Hamouda NN","year":"2015","unstructured":"Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC. Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem. 2015, 400:57-68. 10.1007\/s11010-014-2262-5","journal-title":"Mol Cell Biochem"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman L","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, et al.. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018, 61:722-6. 10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph J","year":"2018","unstructured":"Mustroph J, Wagemann O, L\u00fccht CM, et al.. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018, 5:642-8. 10.1002\/ehf2.12336","journal-title":"ESC Heart Fail"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel S","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, et al.. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018, 20:1690-700. 10.1002\/ejhf.1328","journal-title":"Eur J Heart Fail"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert K","year":"2021","unstructured":"Philippaert K, Kalyaanamoorthy S, Fatehi M, et al.. Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021, 143:2188-204. 10.1161\/CIRCULATIONAHA.121.053350","journal-title":"Circulation"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne NJ","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH, et al.. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020, 13:e006277. 10.1161\/CIRCHEARTFAILURE.119.006277","journal-title":"Circ Heart Fail"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta D","year":"2020","unstructured":"Cappetta D, De Angelis A, Ciuffreda LP, et al.. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol Res. 2020, 157:104781. 10.1016\/j.phrs.2020.104781","journal-title":"Pharmacol Res"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01989-6","article-title":"Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes","volume":"98","author":"Pabel S","year":"2020","unstructured":"Pabel S, Reetz F, Dybkova N, et al.. Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes. J Mol Med (Berl). 2020, 98:1689-700. 10.1007\/s00109-020-01989-6","journal-title":"J Mol Med (Berl)"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes","volume":"7","author":"Trum M","year":"2020","unstructured":"Trum M, Riechel J, Lebek S, et al.. Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes. ESC Heart Fail. 2020, 7:4429-37. 10.1002\/ehf2.13024","journal-title":"ESC Heart Fail"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2023.2181537","article-title":"In search of mechanisms to explain the unquestionable benefit derived from sodium-glucose cotransporter-2 (SGLT-2) inhibitors use in heart failure patients","volume":"135","author":"Lopez-Candales A","year":"2023","unstructured":"Lopez-Candales A, Sawalha K, Drees BM, Norgard NB. In search of mechanisms to explain the unquestionable benefit derived from sodium-glucose cotransporter-2 (SGLT-2) inhibitors use in heart failure patients. Postgrad Med. 2023, 135:323-6. 10.1080\/00325481.2023.2181537","journal-title":"Postgrad Med"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure","volume":"2","author":"Verma S","year":"2017","unstructured":"Verma S, McMurray JJ, Cherney DZ. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol. 2017, 2:939-40. 10.1001\/jamacardio.2017.1891","journal-title":"JAMA Cardiol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam CS","year":"2019","unstructured":"Lam CS, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019, 8:e013389. 10.1161\/JAHA.119.013389","journal-title":"J Am Heart Assoc"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009156","article-title":"Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the Empire HF randomized clinical trial","volume":"15","author":"Omar M","year":"2022","unstructured":"Omar M, Jensen J, Burkhoff D, et al.. Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the Empire HF randomized clinical trial. Circ Heart Fail. 2022, 15:e009156. 10.1161\/CIRCHEARTFAILURE.121.009156","journal-title":"Circ Heart Fail"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","volume":"117","author":"Chung YJ","year":"2021","unstructured":"Chung YJ, Park KC, Tokar S, et al.. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. 2021, 117:2794-806. 10.1093\/cvr\/cvaa323","journal-title":"Cardiovasc Res"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal M","year":"2014","unstructured":"Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014, 20:1126-67. 10.1089\/ars.2012.5149","journal-title":"Antioxid Redox Signal"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000055318.09997.1f","article-title":"Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes","volume":"107","author":"Suematsu N","year":"2003","unstructured":"Suematsu N, Tsutsui H, Wen J, et al.. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation. 2003, 107:1418-23. 10.1161\/01.cir.0000055318.09997.1f","journal-title":"Circulation"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice","volume":"69","author":"Sun X","year":"2020","unstructured":"Sun X, Han F, Lu Q, et al.. Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes. 2020, 69:1292-305. 10.2337\/db19-0991","journal-title":"Diabetes"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110642","article-title":"Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway","volume":"501","author":"Lu Q","year":"2020","unstructured":"Lu Q, Liu J, Li X, et al.. Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway. Mol Cell Endocrinol. 2020, 501:110642. 10.1016\/j.mce.2019.110642","journal-title":"Mol Cell Endocrinol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani CN","year":"2020","unstructured":"Koyani CN, Plastira I, Sourij H, et al.. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. 2020, 158:104870. 10.1016\/j.phrs.2020.104870","journal-title":"Pharmacol Res"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function\u00a0in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn D","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, et al.. Empagliflozin improves endothelial and cardiomyocyte function\u00a0in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021, 117:495-507. 10.1093\/cvr\/cvaa123","journal-title":"Cardiovasc Res"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115437","article-title":"Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a","volume":"22","author":"Goerg J","year":"2021","unstructured":"Goerg J, Sommerfeld M, Greiner B, et al.. Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a. Int J Mol Sci. 2021, 22:10.3390\/ijms22115437","journal-title":"Int J Mol Sci"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman L","year":"2019","unstructured":"Uthman L, Nederlof R, Eerbeek O, et al.. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res. 2019, 115:1533-45. 10.1093\/cvr\/cvz004","journal-title":"Cardiovasc Res"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-019-0733-2","article-title":"Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization","volume":"114","author":"Baker HE","year":"2019","unstructured":"Baker HE, Kiel AM, Luebbe ST, et al.. Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol. 2019, 114:25. 10.1007\/s00395-019-0733-2","journal-title":"Basic Res Cardiol"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam MA","year":"2021","unstructured":"Azam MA, Chakraborty P, Si D, et al.. Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sci. 2021, 276:119440. 10.1016\/j.lfs.2021.119440","journal-title":"Life Sci"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink HJ","year":"2018","unstructured":"Heerspink HJ, Kosiborod M, Inzucchi SE, Cherney DZ. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018, 94:26-39. 10.1016\/j.kint.2017.12.027","journal-title":"Kidney Int"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.03.022","article-title":"SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review","volume":"72","author":"Alicic RZ","year":"2018","unstructured":"Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review. Am J Kidney Dis. 2018, 72:267-77. 10.1053\/j.ajkd.2018.03.022","journal-title":"Am J Kidney Dis"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink HJ","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016, 134:752-72. 10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon V","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017, 60:215-25. 10.1007\/s00125-016-4157-3","journal-title":"Diabetologia"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck L","year":"2017","unstructured":"Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, Joles JA. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017, 28:1023-39. 10.1681\/ASN.2016060666","journal-title":"J Am Soc Nephrol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon V","year":"2020","unstructured":"Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020, 16:317-36. 10.1038\/s41581-020-0256-y","journal-title":"Nat Rev Nephrol"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney DZ","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al.. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014, 129:587-97. 10.1161\/CIRCULATIONAHA.113.005081","journal-title":"Circulation"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel EJ","year":"2020","unstructured":"van Bommel EJ, Muskiet MH, van Baar MJ, et al.. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020, 97:202-12. 10.1016\/j.kint.2019.09.013","journal-title":"Kidney Int"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00482.x","article-title":"Efferent arteriole tubuloglomerular feedback in the renal nephron","volume":"59","author":"Ren Y","year":"2001","unstructured":"Ren Y, Garvin JL, Carretero OA. Efferent arteriole tubuloglomerular feedback in the renal nephron. Kidney Int. 2001, 59:222-9. 10.1046\/j.1523-1755.2001.00482.x","journal-title":"Kidney Int"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"K\u00f6rner A","year":"1994","unstructured":"K\u00f6rner A, Ekl\u00f6f AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes. 1994, 43:629-33. 10.2337\/diab.43.5.629","journal-title":"Diabetes"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis","volume":"21","author":"Wang C","year":"2019","unstructured":"Wang C, Zhou Y, Kong Z, Wang X, Lv W, Geng Z, Wang Y. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019, 21:1018-26. 10.1111\/dom.13620","journal-title":"Diabetes Obes Metab"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00551.2017","article-title":"SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism","volume":"314","author":"Layton AT","year":"2018","unstructured":"Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol. 2018, 314:F969-84. 10.1152\/ajprenal.00551.2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.350","article-title":"Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics","volume":"74","author":"Fine LG","year":"2008","unstructured":"Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008, 74:867-72. 10.1038\/ki.2008.350","journal-title":"Kidney Int"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.03.045","article-title":"Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI","volume":"81","author":"Yin WJ","year":"2012","unstructured":"Yin WJ, Liu F, Li XM, et al.. Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. Eur J Radiol. 2012, 81:1426-31. 10.1016\/j.ejrad.2011.03.045","journal-title":"Eur J Radiol"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink HJ","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013, 15:853-62. 10.1111\/dom.12127","journal-title":"Diabetes Obes Metab"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano M","year":"2019","unstructured":"Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019, 139:1985-7. 10.1161\/CIRCULATIONAHA.118.038881","journal-title":"Circulation"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow KM","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJ, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018, 20:479-87. 10.1111\/dom.13126","journal-title":"Diabetes Obes Metab"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet","volume":"60","author":"Han JH","year":"2017","unstructured":"Han JH, Oh TJ, Lee G, et al.. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet. Diabetologia. 2017, 60:364-76. 10.1007\/s00125-016-4158-2","journal-title":"Diabetologia"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon V","year":"2014","unstructured":"Vallon V, Gerasimova M, Rose MA, et al.. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014, 306:F194-204. 10.1152\/ajprenal.00520.2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers CC","year":"2018","unstructured":"Dekkers CC, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJ. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018, 20:1988-93. 10.1111\/dom.13301","journal-title":"Diabetes Obes Metab"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink HJ","year":"2019","unstructured":"Heerspink HJ, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019, 62:1154-66. 10.1007\/s00125-019-4859-4","journal-title":"Diabetologia"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function","volume":"35","author":"Zoppini G","year":"2012","unstructured":"Zoppini G, Targher G, Chonchol M, et al.. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012, 35:99-104. 10.2337\/dc11-1346","journal-title":"Diabetes Care"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao Y","year":"2018","unstructured":"Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, Chen L. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018, 20:458-62. 10.1111\/dom.13101","journal-title":"Diabetes Obes Metab"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:422-34. 10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen AJ","year":"2019","unstructured":"Scheen AJ. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep. 2019, 21:70. 10.1007\/s11886-019-1165-1","journal-title":"Curr Cardiol Rep"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews VB","year":"2017","unstructured":"Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017, 35:2059-68. 10.1097\/HJH.0000000000001434","journal-title":"J Hypertens"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama T","year":"2019","unstructured":"Maruyama T, Takashima H, Oguma H, et al.. Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther. 2019, 21:713-20. 10.1089\/dia.2019.0212","journal-title":"Diabetes Technol Ther"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato T","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, et al.. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018, 17:6. 10.1186\/s12933-017-0658-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.582680","article-title":"Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective","volume":"11","author":"Yu W","year":"2020","unstructured":"Yu W, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol. 2020, 11:582680. 10.3389\/fphar.2020.582680","journal-title":"Front Pharmacol"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov A","year":"2019","unstructured":"Novikov A, Fu Y, Huang W, et al.. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol. 2019, 316:F173-85. 10.1152\/ajprenal.00462.2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox CS","year":"2018","unstructured":"Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018, 7:10.1161\/JAHA.117.007046","journal-title":"J Am Heart Assoc"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood\u00a0pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney DZ","year":"2018","unstructured":"Cherney DZ, Cooper ME, Tikkanen I, et al.. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood\u00a0pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018, 93:231-44. 10.1016\/j.kint.2017.06.017","journal-title":"Kidney Int"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02381-3","article-title":"Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study","volume":"22","author":"Jeong SJ","year":"2021","unstructured":"Jeong SJ, Lee SE, Shin DH, Park IB, Lee HS, Kim KA. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrol. 2021, 22:177. 10.1186\/s12882-021-02381-3","journal-title":"BMC Nephrol"},{"key":"ref157","article-title":"Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors","author":"Padda IS","year":"2024","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. StatPearls, Treasure Island, FL; 2024."},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100477","article-title":"Call to action: understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"13","author":"Khedagi A","year":"2023","unstructured":"Khedagi A, Hoke C, Kelsey M, et al.. Call to action: understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. Am J Prev Cardiol. 2023, 13:100477. 10.1016\/j.ajpc.2023.100477","journal-title":"Am J Prev Cardiol"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: Insights from the Department of Veterans Affairs","volume":"45","author":"Mahtta D","year":"2022","unstructured":"Mahtta D, Ramsey DJ, Lee MT, et al.. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: Insights from the Department of Veterans Affairs. Diabetes Care. 2022, 45:372-80. 10.2337\/dc21-1815","journal-title":"Diabetes Care"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.11.017","article-title":"Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD","volume":"82","author":"Gregg LP","year":"2023","unstructured":"Gregg LP, Ramsey DJ, Akeroyd JM, Jafry SA, Matheny ME, Virani SS, Navaneethan SD. Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD. Am J Kidney Dis. 2023, 82:53-62.e1. 10.1053\/j.ajkd.2022.11.017","journal-title":"Am J Kidney Dis"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008381","article-title":"Patterns of prescribing sodium-glucose cotransporter-2 inhibitors for Medicare beneficiaries in the United States","volume":"14","author":"Sangha V","year":"2021","unstructured":"Sangha V, Lipska K, Lin Z, Inzucchi SE, McGuire DK, Krumholz HM, Khera R. Patterns of prescribing sodium-glucose cotransporter-2 inhibitors for Medicare beneficiaries in the United States. Circ Cardiovasc Qual Outcomes. 2021, 14:e008381. 10.1161\/CIRCOUTCOMES.121.008381","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref162","unstructured":"New insights into prescribing of SGLT2 inhibitors and GLP-1 receptor agonists by cardiologists in 2020. Major barriers limiting role. (2021). Accessed: April 10, 2024: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2021\/01\/19\/14\/27\/new-insights-into-prescribing-of-sglt2-inhibitors-...."},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1120","article-title":"SGLT2 inhibitors in patients with chronic kidney disease and heart disease: a literature review","volume":"18","author":"Kansara A","year":"2022","unstructured":"Kansara A, Mubeen F, Shakil J. SGLT2 inhibitors in patients with chronic kidney disease and heart disease: a literature review. Methodist Debakey Cardiovasc J. 2022, 18:62-72. 10.14797\/mdcvj.1120","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomized clinical trials","volume":"6","author":"Perkovic V","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al.. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomized clinical trials. Lancet Diabetes Endocrinol. 2018, 6:691-704. 10.1016\/S2213-8587(18)30141-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","volume":"20","author":"Yamada T","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, et al.. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021, 20:14. 10.1186\/s12933-020-01197-z","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/435558-in-search-of-commonality-physiological-and-therapeutic-potentials-of-sodium-glucose-transport-protein-2-inhibitors-in-cardiovascular-and-chronic-kidney-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:24:24Z","timestamp":1763745864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/435558-in-search-of-commonality-physiological-and-therapeutic-potentials-of-sodium-glucose-transport-protein-2-inhibitors-in-cardiovascular-and-chronic-kidney-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":171,"URL":"https:\/\/doi.org\/10.7759\/cureus.97446","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}